New Century Rating: Follow Huahai Pharmaceutical Company and related personnel receiving a warning letter from the Zhejiang Securities Regulatory Bureau
New Century Rating is concerned that on April 19, 2024, Huahai Pharmaceutical issued the “Notice of Zhejiang Huahai Pharmaceutical Co., Ltd. on the receipt of a warning letter from the Zhejiang Securities Regulatory Bureau”. Some of the idle funds temporarily used to supplement working capital have been used for more than 12 months, involving an amount of 11.5 million yuan. The company's chairman Li Hong, general manager Chen Baohua, chief financial officer Zhang Mei, and board secretary Zhu Yonghua are mainly responsible for these irregularities. The Zhejiang Securities Regulatory Bureau decided to take separate supervisory and administrative measures to issue warning letters against the company and the relevant personnel mentioned above, and record them in the securities and futures market integrity file.
Express News | Huahai Pharmaceutical: A subsidiary obtained clinical trial license for injectable HB0052
Huahai Pharmaceutical Gets Approval to Market Busulfan Injection
Zhejiang Huahai Pharmaceutical (SHA:600521) received a drug registration certificate from China's National Medical Products Administration for its busulfan injection, according to the company's disclo
Huahai Pharmaceutical (600521.SH): Busulan injection obtained a drug registration certificate
Gelonghui, April 23 | Huahai Pharmaceutical (600521.SH) announced that the company recently received the “Drug Registration Certificate” for the Bexuan injection approved and issued by the State Drug Administration. Busulinan injection is suitable for use with cyclophosphamide as a pretreatment plan for hematopoietic progenitor cells of chronic myeloid leukemia before transplantation.
Express News | The period of use of 11.5 million idle funds raised for temporary replenishment has been over 12 months. Huahai Pharmaceutical and the chairman of the board have been issued a warning letter by the Zhejiang Securities Regulatory Bureau
Express News | Huahai Pharmaceutical: The company and related personnel received a warning letter from the Zhejiang Securities Regulatory Bureau
Huahai Pharmaceutical (600521.SH) completed the repurchase of 7.023,600 shares at a cost of about 100 million yuan
Huahai Pharmaceutical (600521.SH) announced that on April 17, 2024, the company completed the repurchase and actually repurchased the public...
Investors Continue Waiting On Sidelines For Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521)
It's not a stretch to say that Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) price-to-earnings (or "P/E") ratio of 27x right now seems quite "middle-of-the-road" compared to the market in
Zhejiang Huahai Pharmaceutical Gets Chinese Registration Nod for Torsemide Tablets
Zhejiang Huahai Pharmaceutical (SHA:600521) obtained drug registration approval from China's medical products association for its torsemide tablets, according to a Wednesday filing with the Shanghai b
Zhejiang Huahai Pharmaceutical Forecasts Up to 65% Rise in Q1 Profit
Zhejiang Huahai Pharmaceutical (SHA:600521) forecasts its attributable profit to increase 50% to 65% to between 259.5 million yuan and 285.5 million yuan in the first quarter from 172.9 million yuan i
Shyndec Pharmaceutical's Unit Gets Nod to Register Empagliflozin Tablets
Zhejiang Huahai Pharmaceutical (SHA:600521) obtained a drug registration certificate from China's National Medical Products Administration for its empagliflozin tablets, according to the company's fil
Huahai Pharmaceutical (600521.SH) obtained torasemide tablet drug registration certificate
Huahai Pharmaceutical (600521.SH) issued an announcement. The company recently received the “Drug Registration Certificate” for torasemide tablets approved and issued by the State Drug Administration. Torasemide tablets are used to treat oedema associated with heart failure, kidney disease, or liver disease; for treating high blood pressure, this product can be used alone or in combination with other antihypertensive drugs.
Huahai Pharmaceutical (600521.SH): Empagliflozin tablets obtained drug registration certificate
Gelonghui, April 15, 丨 Huahai Pharmaceutical (600521.SH) announced that it has recently received the “Drug Registration Certificate” for englicin tablets approved and issued by the State Drug Administration. Engagliptin tablets are used to treat adult patients with type 2 diabetes and heart failure.
Huahai Pharmaceutical (600521.SH): Net profit for the first quarter is expected to increase by about 50% to 65% year-on-year
Gelonghui, April 15 | Huahai Pharmaceutical (600521.SH) announced that according to preliminary estimates by the financial department, the company's net profit attributable to shareholders of listed companies in the first quarter of 2024 is expected to be between RMB 259.5 million and RMB 285.5 million. Compared with the same period last year (statutory disclosure data), it will increase by about RMB 86.57 million to RMB 112.57 million, an increase of about 50% to 65% over the previous year. The company's net profit for the first quarter of 2024, which is attributable to shareholders of listed companies after deducting non-recurring profit and loss, is expected to be between RMB 292.2 million and RMB 320.5 million, the same period as the previous year (statutory disclosure
Express News | Huahai Pharmaceutical: Results for the first quarter of 2024 are expected to increase by 55% to 70%
Huahai Pharmaceutical (600521.SH) has spent 99.9851 million yuan to buy back 7.023,300 shares
Huahai Pharmaceutical (600521.SH) issued an announcement. As of March 31, 2024, the company has made a total number of repurchases...
Express News | Huahai Pharmaceutical: The subsidiary's key phase III clinical trial of HB0017 (IL-17A monoclonal antibody) injection ushered in the first case of the test subject
Earnings Are Growing at Zhejiang Huahai Pharmaceutical (SHSE:600521) but Shareholders Still Don't Like Its Prospects
As an investor its worth striving to ensure your overall portfolio beats the market average. But if you try your hand at stock picking, your risk returning less than the market. Unfortunately, that'
Huahai Pharmaceutical (600521.SH): Torasemide injection obtained drug registration certificate
Huahai Pharmaceutical (600521.SH) announced that the company recently received the approval and issuance of Torasepam by the State Drug Administration...
Changxing Pharmaceutical, a subsidiary of Huahai Pharmaceutical (600521.SH), increased 10.74% year-on-year in 2023 net profit of 669.17,400 yuan
Huahai Pharmaceutical (600521.SH) issued an announcement stating that the company's holding subsidiary Changxing Pharmaceutical Co., Ltd. (abbreviation “...
No Data